449 filings
Page 3 of 23
8-K
mg09lvn dwie
10 Mar 23
Regulation FD Disclosure
5:59pm
8-K
txbgex2fsi m9wl4
7 Mar 23
DBV Technologies Announces First Patient
5:09pm
8-K
oqs875170ig iolv
2 Mar 23
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
6:29pm
SC 13G/A
r7jjbfvyhyrl3 0t
14 Feb 23
DBV Technologies / Venrock Healthcare Capital Partners II ownership change
4:31pm
SC 13G
3t48 r9gtw29p1x
14 Feb 23
DBV Technologies / BRAIDWELL ownership change
4:07pm
8-K
6ocw363ddh2c5xewmg
23 Dec 22
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
9:59am
8-K
n95ot3ryah6aishl4j
3 Nov 22
DBV Technologies Reports Third Quarter Financial Results and Business Update
5:18pm
3
sil9jjvfcun5x
6 Oct 22
DBV Technologies / Daniele Guyot-Caparros ownership change
4:23pm
8-K
wdole c3s5v
4 Oct 22
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
7:32am
8-K
x8tjg0is
21 Sep 22
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
7:49pm
8-K
5h0o2tt0d
7 Sep 22
DBV expects to screen the first patient in Q4 2022 and anticipates topline results for the VITESSE study to read out in Q1 2025
7:09pm
EFFECT
0gxshkqm
12 Aug 22
Notice of effectiveness
12:15am
EFFECT
npvd0k3
12 Aug 22
Notice of effectiveness
12:15am
424B3
kfgsu08hj4cyw a2i
11 Aug 22
Prospectus supplement
4:34pm
424B3
d0iv3585da 3b5
11 Aug 22
Prospectus supplement
4:30pm
CORRESP
f84l58e0gqqbkf yly3
9 Aug 22
Correspondence with SEC
12:00am